DiaMedica Therapeutics Inc.
DMACHealthcareNASDAQBiotechnology · Last scanned Sep 7, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, DiaMedica Therapeutics Inc. focuses on Biotechnology services and products. DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. At a $364.0M market cap, DiaMedica Therapeutics Inc. ranks as a small-cap company within healthcare. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
Market Cap
$364.0M
Beta
0.97
P/E (TTM)
—
P/E (Fwd)
-8.35
EPS (TTM)
$-0.72
EPS (Fwd)
$-0.81
ROE
-114.6%
ROA
-64.1%
Cash
$43.5M
Total Debt
$185,000
Free CF
-$17.6M
52W Change
-6.4%
Annual Financials
Cash vs Debt
Where DMAC stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, DMAC finished 5.84% below its 150-day moving average ($6.85) and 10.29% below its 200-day moving average ($7.19). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DMAC overbought or oversold?
At the September 2, 2026 close, DMAC's RSI(14) was 37.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $43.5M in cash comfortably exceeding the $185K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$17.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -114.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, DMAC has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing DMAC.